WHAT TO WATCH FOR: Amgen executives likely will note a new approval for an existing drug, discuss their strategy to expand overseas sales and give updates on testing of drugs including trebananib for ovarian cancer and TVEC. That's short for the tongue twister talimogene laherparepvec, a promising drug for melanoma.
The company, based in
Amgen, the world's biggest biotech company by revenue, is looking to get even bigger, announcing plans in February to expand its operations in
Amgen, which makes Prolia for osteoporosis, two months ago said it started a strategic alliance with Japanese drugmaker
The first might hit the market by 2016. The companies plan for Astellas to become a wholly owned subsidiary of Amgen as soon as 2020.
While Amgen has mainly specialized in medicines for cancer and bone and immune disorders, it appears it's now trying to become a player in the huge market for heart drugs.
Earlier this month, Amgen announced a collaboration with French drugmaker
And in June, Amgen and
Analysts likely will ask about rumors and news reports that Amgen is trying to acquire cancer drugmaker
WHY IT MATTERS: Unlike most big pharmaceutical companies, Amgen has not been hurt by generic competition cutting into sales of its products. That's because all but one of its medicines are biologic drugs produced by living cells, rather than pills that are easy to copy. But regulatory changes spelling out what companies need to do to get approval of "biosimilar" versions of these pricey drugs mean Amgen is likely to face such competition in a couple years.
In the meantime, it's been trying to broaden its product portfolio by advancing its experimental drugs and arranging some acquisitions and partnerships.
In addition, investors have been watching to see whether
WHAT'S EXPECTED: Analysts polled by FactSet, on average, expect earnings per share of
LAST YEAR'S QUARTER: Amgen reported net income of
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- TFA Recruiting DACA Recipients
- Scotch Whisky Sales Raise Distillers' Spirits
- Holiday Shopping Off to a Slow Start This Season
- Fake Deaf Interpreter Was Hallucinating, Has Schizophrenia
- Tea Party Glum in Face of Bipartisan Budget Deal
- Budget Deal Will Cut 220,000 Californians Out of Jobless Benefits
- Health Coverage Disparities Emerge Among States